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Nonylphenol (NP) and octylphenol (OP) are pervasive environmental contaminants belonging to the broader class of compounds
known as alkylphenols, with potential human toxic effects. Classified as “xenoestrogens,” NP and OP are able to interfere with the
cell endocrine physiology via a direct interaction with the estrogen receptors. Here, using HepG2 cells in culture, the changes of the
cell redox balance and mitochondrial activity induced by OP and NP have been investigated at μM concentrations, largely below
those provoking acute toxicity, as those typical of environmental contaminants. Following 24 h cell exposure to both OP and
NP, ROS production appeared significantly increased (p ≤ 0 01), together with the production of higher NO oxides (p = 0 003)
and peroxynitrated protein-derivatives (NP versus CTR, p = 0 003). The mitochondrial proton electrochemical potential
gradient instead was decreased (p ≤ 0 05), as the oxygen consumption by complex IV, particularly following incubation with
NP (NP versus CTR, p = 0 017). Consistently, the RT-PCR and Western blot analyses proved that the OP and NP can
modulate to a different extent the expression of the inducible NOS (NP versus CTR, p ≤ 0 01) and the endothelial NOS (OP versus
CTR, p ≤ 0 05), with a significant variation of the coupling efficiency of the latter (NP versus CTR, p ≤ 0 05), a finding that may
provide a novel clue to understand the specific xenoestrogenic properties of OP and NP.
1. Introduction
Long-chain alkylphenols (APs), such as the octylphenol (OP)
and the nonylphenol (NP), belong to a family of compounds
widely used by industry to optimize manufacturing of com-
mon products including plastics, lubricants, detergents, cos-
metics, and also herbicides [1]. Approximately 80% of the
synthesized APs are represented by NP, the remaining 20%
being constituted by OP [2]. Once dispersed in the environ-
ment, these compounds migrate into the soil and water
through evaporation, leading to environmental contamina-
tion. In aquatic ecosystems, APs can be found on the order
of a few to several hundreds of ng/L, whereas in agriculture
soil, depending on irrigation and treatments, concentrations
may reach magnitudes of μg or even mg/Kg [3–8]. In human
tissues, bioaccumulation of APs occurs via ingestion, inhala-
tion, and dermal absorption. Recent studies have shown the
presence of OP and NP both in the maternal blood plasma
and in the amniotic fluid, at concentrations reaching μM
values (from ~0.5 to 100ng/mL), and contamination of
human breast milk has also been reported [9–11]. Owing to
their chemical structural similarity to natural estrogens, OP
and NP have been included in the family of the endocrine dis-
rupting chemicals (EDCs), a group of substances that inter-
fere with the synthesis, secretion, transport, metabolism,
binding, action, and elimination of natural hormones [12].
More specifically, NP and OP have been defined as “xenoes-
trogens,” since their phenolic moiety can mimic the 17β-
estradiol (E2) in its interaction with the estrogen receptors
(ERs), thus envisaging agonistic or antagonistic activity at
the level of the target tissues [13–16]. ERs have been found
embedded in the plasma membrane, as well as in the cell
cytoplasm and mitochondria [17–19]. Their main location,
however, is in the nucleus, where through recognition of
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estrogen responsive elements (EREs) [20, 21] or by the inter-
action with transcription factors, they may induce specific,
different, and/or overlapping physiological effects [22, 23].
In mitochondria, estrogens proved to control several
physiological areas such as the regulation of mitochondrial
biogenesis, the expression of respiratory chain complexes,
and the maintenance of the cell redox homeostasis [24–28].
Several studies have shown a correlation between the
estrogen receptors and the nitric oxide metabolism [29–33].
It has been observed that in the presence of physiological
concentrations of 17-β estradiol (E2), the expression and
activity of endothelial nitric oxide synthase (eNOS) are
increased and that these effects are mediated by the ERα sub-
type of ERs [34, 35]. Other studies showed that ERs act as
transcription factors also for the inducible nitric oxide syn-
thase (iNOS) [36]. It was also noted that the ERα, associated
with the membrane at the caveolae level, activates the path-
way PI3K/AKT, which, in turn, leads to phosphorylation
on serine 1177 (S1177) of eNOS [37, 38]. Relevant to the
results shown in this paper, this phosphorylation mechanism
stabilizes the eNOS structure optimizing its function, thus
the physiological NO production [39, 40].
The NO metabolism is crucial to a number of physiolog-
ical responses [41] such as blood vessel contractility [42],
immune response [43], and neuronal functions [44–46].
In synergy with the activity of the other gaseotransmit-
ters H2S and CO [47, 48], NO plays a fundamental role in
cell signaling, especially in the control of mitochondrial
function through a direct interaction with complexes I and
IV [49–54].
The pathophysiological implication of NO depends on its
bioavailability, particularly on the generation of reactive oxy-
gen species (ROS) and reactive nitrogen species (RNS). At
low concentrations (nM), as those generated by the constitu-
tive NOS isoforms (nNOS, eNOS), NO acts as a physiological
effector [55–58]. On the contrary, at higher concentrations
(μM), as those reached following iNOS activation [59], toxic
effects appear due to a persistent OXPHOS inhibition; under
these conditions, the overproduction of ROS and RNS is
expected [60].
The investigation of the crosstalk among the NO signal-
ing and the estrogen pathway represents a suitable approach
to clarify the molecular mechanism(s) through which NP
and OP may interfere with cell physiology.
Recently, the correlation between the increased incidence
of reproductive system disorders, including breast, ovarian,
and testis cancers, and the exposure to OP and NP has been
highlighted [13, 61–63], but little is known about the mecha-
nisms involved. Following OP and NP exposure, both direct-
and receptor-mediated effects on the endocrine system have
been described [64]; these consist in an altered inflammatory
response and increased level of ROS, prevented by the use of
antioxidants [2, 65, 66].
In this work, the OP and NP mechanisms of toxicity
have been investigated with reference to their proposed
xenoestrogenic action and focusing on their potential ability
to interfere with the NO signaling. A human hepatocellular
cancer-derived cell line (HepG2) expressing ERs [67–70]
was the model system used to assess the effects of AP
exposure. Following OP and NP incubation, the expression
and activity of factors involved in the cell nitro/oxidative
metabolism were assessed.
Particular effort was made to detect specific posttransla-
tional modifications on eNOS, as indicative of its uncoupling.
The mitochondrial functional state of cells undergoing
OP and NP exposure was evaluated by following the oxygen
consumption rate and the mitochondrial membrane poten-
tial built up at equilibrium.
2. Methods
2.1. Cell Culture. The human hepatocellular cancer-derived
cell line (HepG2 ATCC® HB-8065™) was maintained in Dul-
becco’s modified Eagle medium (DMEM) supplemented
with 2mM L-glutamine, 10% heat-inactivated fetal bovine
serum (FBS), and 1% antibiotics of 50U/mL penicillin and
50μg/mL streptomycin in a 37°C, 5% CO2, 95% air cell cul-
ture incubator. Cells were incubated in the presence and
absence of OP (10μM), NP (20μM), and E2 (1μM). In
the case of dose-response analysis, cells were grown with
increasing concentrations and times of incubation of OP
and NP (see next). Eventually, cells were coincubated with
Flv (1μM). When necessary, HepG2 cells were washed by
phosphate-buffered saline (PBS), harvested by trypsinization
and centrifugation (1000×g), and carefully suspended in the
working medium, at suitable density (see text). Cell lysis was
performed by CelLytic™ M cell lysis reagent in the presence
of the protease inhibitor cocktail; protein content was deter-
mined according to the bicinchoninic acid (BCA) assay.
2.2. Cell Viability Assay. The viability of HepG2 cells was
assessed using the MTT (3(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) reduction assay as described
in [71]. Briefly, cells (2× 105/mL) were seeded in a 96-well
plate in a final volume of 100μL/well and incubated for dif-
ferent time at 37°C in the presence or absence of increasing
OP and NP concentrations, in the μM range, until 1mM in
the case of NP. At the end of the incubation, 10μL of MTT
solution (5mg/mL) was added to each well, followed by 4h
incubation at 37°C. Afterwards, cells were incubated for
30min in the dark at 37°C, with 100μL of dimethyl sulfoxide
(DMSO) in order to dissolve the dark-coloured formazan
crystals produced by reduction of the MTT tetrazolium salt.
The optical density of reduced MTT was measured at
570 nm with a reference wavelength at 690 nm using Applis-
kan Microplate Reader (Thermo Scientific).
2.3. Real-Time PCR. HepG2 cells were assayed for total RNA
extraction using Nucleo Spin® RNA isolation (Macherey-
Nagel, Germany) according to the manufacturer instruc-
tions, after incubation with OP (10μM) or NP (20μM) for
12 h or 24h, or untreated. 1μg of total RNA was used for
reverse transcription reaction using RT2 First Strand Kit
(Qiagen). Real-Time PCR (RT-PCR) was performed using
primers designed by BioRad Laboratories (Software Beacon
Designer) and purchased by PRIMM. SYBR green-based
QRT-PCR (Brilliant_SYBR_Green QPCR Master Mix,
Stratagene) was performed using a Stratagene Mx3005p
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System (Agilent Technologies). The cDNAs were amplified
using 45 cycles consisting of denaturation step (95°C for
5min) and amplification step (95°C for 10 sec, 55°C for
30 sec). Melting curve analysis was performed at the end of
every run to ensure a single amplified product for each reac-
tion. β-Actin gene (PRIMM) was used for normalization.
The primers used in this study are as follows: nNOS
(NOS1): forward: 5′ GCGGTTCTCTATAGCTTCCAGA 3′,
reverse: 5′ CCATGTGCTTAATGAAGGACTCG 3′; iNOS
(NOS2): forward: 5′ CCGAGTCAGAGTCACCATCC 3′,
reverse: 5′ CAGCAGCCGTTCCTCCTC 3′; eNOS (NOS3):
forward: 5′ GCCGTGCTGCACAGTTACC 3′, reverse: 5′
GCTCATTCTCCAGGTGCTTCAT 3′; and β-actin: for-
ward: 5′ GCGAGAAGATGACCCAGATC 3′, reverse: 5′ G
GATAGCACAGCCTGGATAG 3′.
2.4. Western Blot.After 24 h incubation with OP (10μM), NP
(20μM), and E2 (1μM), in the presence or absence of Flv
(1μM), HepG2 cells (3× 106 cells) were lysed with CelLytic
M reagent (Sigma) in the presence of protease inhibitors
(Sigma). The proteins (40μg) were separated on 10% SDS-
PAGE gels and transferred on nitrocellulose membranes
(Whatman, GE Healthcare, UK) 1h at 150mA. After 2 h in
blocking solution (PBS with 0.1% tween and 3% BSA), the
membrane was incubated overnight at 4°C with primary
rabbit polyclonal anti-iNOS antibody (from Boster Biological
Technology) or with primary mouse monoclonal anti-
phospho-Ser1177 (P-Ser 1177) and anti-phospho-Thr495
(P-Thr 495) antibodies (both from BD Transduction Labora-
tories) and was stripped and reprobed for monoclonal puri-
fied mouse anti-eNOS antibodies (from BD Transduction
Laboratories). α-Tubulin was used as loading control. A sec-
ondary ECL TM anti-rabbit or anti-mouse antibody HRP
(Jackson, Baltimore, PA, USA) was thereafter incubated 1 h
at 25°C to be determined by chemiluminescence (Amersham,
GE Healthcare, UK). Densitometric analysis was carried out
by the ChemiDoc™ MP image analysis software (Bio-Rad).
2.5. Reactive Oxygen Species (ROS) Quantification. Genera-
tion of ROS in HepG2 cells was measured after 24 h exposure
toOP (10μM) andNP (20μM)by using the fluorescent probe
2′,7′-dichlorodihydrofluorescein diacetate (DCFDA, Sigma-
Aldrich) in 24-well (black) plates. The relative fluorescence
emission, after cell loading of DCFDA 10μM, was followed
at 520nm (VICTOR™Multilabel Counter, Perkin Elmer).
2.6. Nitrate/Nitrite (NOx) Determination. The nitrate/nitrite
(NOx) accumulation in the culture medium of HepG2 cells
(~2.5× 105 cells/mL) was measured after OP and NP treat-
ment as previously described. After incubation, the cell
supernatants were centrifuged at 4°C, 1000×g for 10min,
and the NOx content was measured at the Fluorescence Plate
Reader VICTOR Multilabel Counter (Perkin Elmer) using
the fluorescent probe DAN (2,3-diaminonaphthalene) (Fluo-
rimetric Assay Kit, Cayman Chemical) [72].
2.7. 3-Nitrotyrosine Level Detection. The content in 3-nitro-
tyrosine- (3-NT-) modified proteins was used as marker of
protein damage by peroxynitrite in HepG2 exposed to OP
and NP or control cells. After treatments, HepG2 cells were
trypsinized, pelleted at 500×g for 10min, and washed twice
with PBS buffer. Cell pellets (1× 106 cells) were resuspended
with extraction buffer and incubated on ice for 20min. After
centrifugation at 12.000×g 4°C for 20min, the 3-NT levels
were assessed colorimetrically using a competitive Nitrotyro-
sine ELISA kit (Abcam ab113848).
2.8. Oxygen Consumption Measurements. Oxygen consump-
tion of HepG2 cells was measured with the OROBOROS
Oxygraph 2k (Oroboros Instruments). The contribution of
the respiratory complexes to cell respiration was evaluated
according to Kuznetsov et al. with minor modifications
[73, 74]. Briefly, HepG2 cells, treated in the presence and
absence of OP and NP, were harvested and resuspended in
a medium consisting of 3mM MgCl2× 6 H2O, 10mM
KH2PO4, 20mM HEPES, 1 g/L BSA, 110mM mannitol, and
0.5mM EGTA, at pH7.1. Cell density was determined by cell
count (Thoma cell counting chamber), and cell viability was
evaluated by the trypan blue exclusion test. Cell suspensions
were added to the oxygraph chambers at the final cell density
of 3× 106 cells/mL. Basal respiration was measured, and sub-
sequently cells were permeabilised by digitonin addition. The
optimal digitonin concentration of 20μg/mL and incubation
time, 10min, were previously determined as described by
Gnaiger et al. [75]. Pyruvate and malate at the final concen-
tration of 8.8mM and 4.4mM, respectively, were added to
determine the resting complex I-supported respiration (state
IV). ADP was added to reach the saturating concentration of
2mM and obtain the maximal mitochondrial respiration
(state III). Rotenone (0.5μM), a specific inhibitor of complex
I, was added to inhibit respiration. By the addition succinate
(10mM), the complex II-supported respiration was acti-
vated. Antimycin A (5μM) was then added to inhibit com-
plex III. The stimulation of complex IV-driven respiration
was then obtained by adding 2mM ascorbate and 0.5mM
N,N,NV,NV-tetramethyl-p-phenylenediamine hydrochlo-
ride (TMPD).
2.9. Mitochondrial Membrane Potential Measurements.
Mitochondrial membrane potential was measured by flow
cytometry (Accuri C6 Flow Cytometer®) using cells stained
with the fluorescent cationic probe JC-1 [76, 77]. Briefly, after
treatments with OP and NP, HepG2 were trypsinized, pel-
leted at 1000×g for 5min at 20°C, and resuspended in PBS
buffer at the density 5× 105 cells/mL. Cell suspensions were
incubated 20min in the dark with JC-1 2.5μg/mL, washed
two times, and resuspended in 300μL PBS. JC-1 was excited
at 488 nm, green fluorescence was quantified 530 nm (FL1
channel), and red fluorescence was quantified at 585 nm
(FL2 channel).
2.10. Statistical Analysis. Data are the mean± SEM of at
least three independent biological experiments (as specified
in the figure legends), each repeated in three technical rep-
licates. For statistical analysis, one-way analysis of variance
(ANOVA), followed by Bonferroni-Holm post hoc test,
was used for multiple comparisons. p values indicated in
figures were considered statistically significant by ANOVA.
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3. Results
3.1. Determination of the Subtoxic Concentrations of NP and
OP in HepG2 Cells. The viability of HepG2 cell exposed 24 h
to OP and NP was determined by the MTT assay. A dose-
response analysis was performed by incubating the cells to
increasing concentrations of each alkylphenol (Figures 1(a)
and 1(b)).
Grossly, the OP and NP concentration, corresponding
to 50% of inhibition of cell viability, was ~26μM and
750μM, respectively.
Based on these results, the concentration of OP and NP
utilized in the experiments herein reported was set at 10 and
20μM, respectively, that is, values subtoxic on the experi-
mental time scale chosen (Figure 1(c)).
3.2. mRNA Expression of the Endothelial and the Inducible
Nitric Oxide Synthase. The mRNA for the two different iso-
forms of nitric oxide synthase (NOS) expressed in HepG2
cells, the endothelial NOS and the inducible NOS (eNOS
and iNOS), was determined after 12 h and 24 h incubation
of the cells with OP and NP. After 24 h incubation with OP,
a 1.6-fold increase of eNOS and 1.4-fold increase of iNOS
mRNA biosynthesis were observed (Figure 1(d)). eNOS
mRNA expression is only slightly affected (within 10–20%)
by NP, whereas the iNOS mRNA is almost doubled
(Figure 1(d)). The mRNA for the neuronal isoform of NOS
(nNOS) remained almost undetectable under all conditions
(not shown).
A shorter incubation time (12 h) with both compounds
did not significantly affect the NOS’s mRNA compared to
untreated cells (Supplementary Figure 1).
3.3. eNOS/iNOS Protein Expression and eNOS Uncoupling.
Following HepG2 cell incubation with OP and NP, the iNOS
and eNOS protein expression level has been evaluated by
Western blot. As shown in Figure 2(a), OP induces a ~1.5-
fold increase of the eNOS protein expression, whereas the
variation on the iNOS synthesis is negligible. On the con-
trary, the incubation with NP, almost ineffective on the eNOS
expression, induces a ~1.5-fold increase of the iNOS protein
expression. These data are consistent with the mRNA results
shown in Figure 1(d).
The occurrence of regulative modifications at the level
of specific amino acid residues of eNOS was investigated
by Western blot in HepG2 exposed to OP and NP. Of
mechanistic interest, a change in the eNOS phosphorylation
at serine 1177 (P-Ser 1177) and at threonine 495 (P-Thr
495) with respect to control is strongly related with the
uncoupling level of protein. The eNOS phosphorylation
level at these sites is reported in Figure 2(b) as the ratio
of phospho-eNOS over total eNOS. The phospho-eNOS at
serine 1177 is about 100% of total eNOS in control cells.
This phosphorylation yield is not significantly affected by
the incubation with OP, whereas it decreases to 70% follow-
ing incubation with NP (Figure 2(b)). In the same figure, it
was shown that the NP treatment provokes a ~25% increase
of P-Thr 495 compared to controls, that is, from ~60% up
to 85%, whereas no significant changes were induced by
OP (Figure 2(b)). In synthesis, these results suggest that
upon exposing the HepG2 cells to NP, the eNOS becomes
significantly uncoupled while OP treatment does not lead
to eNOS uncoupling.
3.4. The β-Estradiol and the Estrogen Receptor Involvement in
the Regulation of NOS Protein Expression and Uncoupling. In
order to investigate if the modification on NOS expression
induced by OP and NP may be related to their endocrine dis-
ruptive effects, we have carried out Western blot experiments
in HepG2 cells treated with the natural estrogen (E2) in the
presence and absence of the ER inhibitor Fulvestrant (Flv).
As shown in Figure 3(a), E2 induced an increase of about
1.7-fold in eNOS protein expression; this result is in good
agreement with previous data already reported in the litera-
ture [29, 30]. It is also shown that the E2-induced increase of
eNOS expression is reversed by the ER inhibitor (p = 0 05),
although not completely. Notably, OP induces an effect sim-
ilar to that of E2 on eNOS protein expression and also in this
case the increased expression of eNOS is lowered by the
coincubation of OP with the ER inhibitor Flv (p = 0 03).
NP does not affect significantly the eNOS expression, and
regardless to Flv presence. As shown in Figure 3(b), the
effect of NP administration specifically targets iNOS protein
expression, as neither E2 nor OP was able to induce this
NOS isoform. Interestingly, the effect of NP on iNOS was
promptly reverted by Flv (Figure 3(b)).
The level of eNOS uncoupling was evaluated by detecting
P-Ser 1177 and P-Thr 495 in HepG2 cells treated 24 h with
E2, OP, and NP in the presence and absence of the ER inhib-
itor Flv. In Figure 3(c), the phosphorylation level of Ser 1177
is shown as relative to the total eNOS independently
detected. In control cells, this ratio is ~1.0, indicating that
under normal conditions, Ser 1177 is fully phosphorylated.
It is interesting to point out that, upon exposing cells to either
the natural E2 or to OP, the Ser 1177 phosphorylation yield
was unchanged and close to 100%, being insensitive to Flv.
In the case of NP, a small decrease (~30%) of the Ser 1177
phosphorylation was observed, only partially (~8%) reverted
by Flv (Figure 3(c)).
Data showed that the basal value for the ratio P-Thr 495
eNOS/total eNOS (~0.6), measured in control cells, was
similar to that measured after E2 and OP treatment and
insensitive to the presence of Flv. Interestingly, and in good
agreement with data in Figure 2(b), the increase in P-Thr
495 induced by NP was prevented by Flv (Figure 3(d)).
Summing up, the results reported in Figure 3 show that
the OP-induced expression of eNOS is reverted by the ER
inhibitor Flv, as it occurs in the presence of the natural estro-
gen, E2. NP does not share with OP the ability to induce
eNOS expression (Figure 3(a)), but it specifically increases
the iNOS expression, a feature prevented by the coincubation
with Flv (Figure 3(b)). Both E2 and OP failed at inducing an
increase of iNOS. Moreover, in E2, OP, and control cells, Ser
1177 is almost 100% phosphorylated and Thr 495 is only 55%
phosphorylated. NP induced a decrease of P-Ser 1177, poorly
sensitive to Flv, together with an increase of P-Thr 495: both
changes are consistent with the onset of a significant eNOS
uncoupling (Figures 3(c) and 3(d)).
4 Oxidative Medicine and Cellular Longevity
3.5. Reactive Oxygen Species, Nitrite/Nitrate, and 3-
Nitrotyrosine Induction by OP and NP. The production of
ROS, the accumulation of NOx, and the formation of 3-
nitrotyrosine derivatives were evaluated in order to assess
the level of oxidative stress putatively induced in HepG2 cells
by OP and NP. Following 24h treatments, the amount of
ROS detected in the cells increased by ~40% (OP) and
~50% (NP) (Figure 4(a)). Over the same time period, the
amount of NO produced by the cells, measured as nitrate
and nitrite (NOx) equivalents in the cell medium, was about
tripled in AP-treated cells compared to controls, with the OP
and NP exerting a similar effect, slightly stronger with NP
(Figure 4(b)). Under otherwise identical conditions, the effect
of OP on 3-NT protein modification was negligible, whereas
NP induced a significant increase of the 3-NT level
(Figure 4(c)).
3.6. Oxygen Consumption Measurements. O2 consumption
measurements were carried out oxygraphically. The involve-
ment of specific mitochondrial respiratory chain complexes
in the OP- and NP-induced cell toxicity was evaluated fol-
lowing the mitochondrial electron transfer (ET) complex-
specific substrate/inhibitor titration approach [73]. The basal
respiration of OP- or NP-treated HepG2 cells was measured
to be compared to that of controls (Figure 5(a)). Cell mem-
brane permeabilisation was then achieved by in-trace addi-
tion of digitonin, to allow substrates and inhibitors to target
specific ET-chain complexes. The values of the O2 consump-
tion rate were recorded following each addition step and
reported in Figure 5(a). Regardless to the AP treatment,
the basal cell respiration was found similar to controls and
a comparable activity for the ETC complexes I, II, and III
resulted in treated and untreated cells. The respiratory con-
trol ratio (RCR) was determined considering the O2 con-
sumption rates recorded in the presence of the complex I
substrates pyruvate and malate (Pyr/Mal), that is, state IV,
and the rate measured after the addition of ADP, that is,
state III. The RCR value, obtained as the ratio state III over
state IV, was found comparable in controls and AP-treated
cells (~2.5).
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Figure 1: Cell viability of HepG2 cells exposed to octylphenol (OP) and nonylphenol (NP) measured with the MTT assay. (a) The OP
dose-response on the HepG2 cell viability (24 h incubation). (b) The NP dose-response on the HepG2 cell viability (24 h incubation).
(c) The time-response on the HepG2 cell viability after the incubation with OP (10 μM) and NP (20 μM). Data± SEM; n = 3. eNOS and
iNOS gene expression in response to OP and NP. (d) The gene expression of endothelial nitric oxide synthase (eNOS) and inducible
nitric oxide synthase (iNOS) has been evaluated in HepG2 cells after 24 h incubation with OP (10 μM) and NP (20 μM). Relative
expression was calculated versus untreated cells (CTR), after β-actin normalization. Data± SEM; n = 3. p values were considered
statistically significant by ANOVA.
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To evaluate the functionality of complex IV, the reduc-
tion of cytochrome c was achieved as a final step of the O2
consumption analysis, through the addition of the reductants
ascorbate and N,N,N′,N′-tetramethyl-p-phenylenediamine
(Asc/TMPD). Under these conditions, the electron delivery
at the complex IV site is optimized, allowing the respiratory
rate to become maximal. At this stage, a lower respiratory
rate has been observed in cells specifically treated with NP
compared to both OP and untreated cells; this difference
accounts for a ~20% deficit of complex IV activity induced
by NP.
3.7. Mitochondrial Membrane Potential of OP- and NP-
Treated HepG2 Cells. The overall cell bioenergetics state
was assessed by measuring the mitochondrial membrane
potential (ΔμH+) of AP-treated cells, by quantifying the
mitochondrial import of the fluorescent probe JC-1 and the
formation of the red J-aggregates. After 24 h cell incubation
with OP and NP, the mitochondrial membrane potential is
lowered by ~28% and 12%, respectively (see Figure 5(b)).
4. Discussion
Recent evidences related to the endocrine disrupting activity
of alkylphenols (APs) recall to the urgency of understanding
the molecular mechanisms by which APs accomplish their
action [2, 12, 78].
In particular, little is known about the effect of octylphe-
nol and nonylphenol on both the cell NO signaling chemistry
and the energetic metabolism, although in either issue the
involvement of the estrogen pathway has been established
[29, 31–36].
In this work, we have addressed the question whether OP
and NP, at concentrations compatible with the environmen-
tal pollution, may interfere with the physiological NO signal-
ing resulting in a cell nitro-oxidative stress and impairment
of mitochondrial function. The experimental design has been
based on cultured HepG2 cells exposed (24 h) to OP, NP, and
to the natural β-estradiol. The main focus was on the charac-
terisation of the eNOS and iNOS expression and activity, as
the complex regulation and crosstalk among the NOS iso-
forms may be considered a reliable marker of cell nitro-
oxidative stress.
According to our results, the APs proved to be bioactive
and dangerous for mammalian cells already at μM concen-
trations, similar to those detected in the body fluids [9, 10].
Under the conditions herein described, cell exposure to OP
resulted in the increased synthesis of both eNOS mRNA
and protein, whereas the iNOS remained unstimulated.
Remarkably, 24 h incubation with NP brought about a large
increase (~2-fold) of the iNOS mRNA found also at protein
level, whereas the eNOS expression remained comparable
to that of controls.
The relevance of the different, reciprocally specular effects
exerted by OP and NP on the eNOS and iNOS expression is
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Figure 2: (a) eNOS and iNOS protein expression and (b) evaluation of eNOS uncoupling, in response to OP and NP. HepG2 were incubated
24 h with OP and NP, 10 and 20 μM, respectively, and assayed by Western blot. (a) eNOS and iNOS protein detection was carried out using
isoform-specific anti-eNOS and anti-iNOS antibodies. Values are reported as fold increase versus the protein expressed by control cells (CTR)
(data± SEM, n = 6). p values were considered statistically significant by ANOVA. (b) Phosphorylation at Ser1177 and Thr495 of eNOS,
determined using anti p-Ser1177 and anti p-Thr495 eNOS-specific antibodies. Values are reported as the ratio of phospho eNOS
(Ser 1177 or Thr 495) over total eNOS (data± SEM, n = 4). p values were considered statistically significant by ANOVA. Inset: typical
Western blot pattern as detected using antibodies against iNOS, eNOS, p-S1177 eNOS, and p-T495 eNOS, and following 24 h cell
incubation with OP and NP; α-tubulin as reference (details in Methods).
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further clarified by the analysis of the NOS isoform biosyn-
thetic pattern induced upon exposing cells to 17β-estradiol.
Incubation with the natural estrogen results in an eNOS
and iNOS expression pattern comparable to that induced
by OP, characterised by the increase of eNOS expression
and a basal iNOS production. In agreement with animal
model studies reported in the literature [33], our data suggest
that OP holds an estrogen mimicking-function [62]. Such a
behavior is not shared by NP, in our hands inducing opposite
(competing) effects.
It is now widely accepted that eNOS may undergo crucial
posttranslational modifications of specific amino acidic tar-
get sites. These interactions regulate its functional activity,
namely, the substrates/cofactor binding properties and the
dimeric structure stability, in response to pathophysiological
stimuli [39, 40, 79, 80]. Among these modifications, phos-
phorylation at residues Ser 1177 and Thr 495 is known to
affect the eNOS enzymatic activity and the degree of uncou-
pling, a condition in which the reaction carried out by the
eNOS leads to the final production of superoxide radical
(O2
−•), instead of NO. The canonical NO-producing func-
tion of eNOS is maintained by the high phosphorylation
levels of Ser 1177 and low phosphorylation levels of Thr
495; the actual values depend on the cell type [39, 60, 80].
As shown in this paper, healthy HepG2 cells, under
basal culture conditions, are endowed with the eNOS,
~100% phosphorylated at Ser 1177 (P-Ser 1177) and 55%
at Thr 495 (P-Thr 495). The presence of OP in the incuba-
tion medium did not affect the relative eNOS phosphoryla-
tion settings, whereas incubation with NP induced the
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Figure 3: Evaluation of the estrogen signal involvement in the NOS’s expression and eNOS phosphorylation. HepG2 cells were incubated
24 h with E2 (1 μM), OP (10 μM), and NP (20 μM) in the absence and presence of Flv (1 μM), and Western blot analysis has been carried
out using antibodies against (a) eNOS, (b) iNOS, (c) P-S1177 eNOS, and (d) P-T495 eNOS; α-tubulin as reference. (a, b) Densitometric
values are shown as fold increase versus the proteins expressed by the control cells. (c, d) Densitometric values are shown as the ratio of
phosphorylated eNOS (at Ser1177 or Thr495)/total eNOS (data± SEM, n≥ 3). p values from Figure 3(a) (not displayed in the picture): E2
versus NP: p = 0 01; OP versus NP: p = 0 0004. p values were considered statistically significant by ANOVA.
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simultaneous decrease of P-Ser 1177 (to 70% of total
eNOS) and the increase of P-Thr 495 (to 80% of total
eNOS). The sharp change of the eNOS phosphorylation
pattern induced by NP treatment strongly suggest eNOS
uncoupling (Figure 2(b)).
From the mechanistic point of view, it is interesting to
outline that the 17β-estradiol, though inducing an increase
of the overall eNOS expression, does not lead to eNOS
uncoupling, thus preserving the eNOS physiological NO-
producing activity. Both the NOS (eNOS and iNOS) expres-
sion and the eNOS phosphorylation were also evaluated in
the presence of the estrogen receptor inhibitor Fulvestrant
(Flv). The observed variations of the eNOS and iNOS expres-
sion were reverted by Flv, indicating the involvement of ERs
in the regulatory pathways of both eNOS and iNOS. The
eNOS posttranslational changes observed in the copresence
of NP and Flv, though less focussed, overall suggest the
involvement of ERs also in the onset of eNOS uncoupling.
In agreement with previous data in the literature [33], our
findings, while consistent with the xenoestrogenic effect
of OP and NP, point to their involvement in the eNOS
and iNOS expression, regulation, and crosstalk, at least in
HepG2 cells.
Downstream effects of APs on cell physiology have been
also investigated measuring markers of oxidative stress and
bioenergetics parameters. The results obtained point to a sig-
nificant increase of ROS production and NOx accumulation
induced by OP and NP. The finding of an OP-induced ROS
increase may be attributed to its proposed E2-mimicking
behaviour, since the estrogenic ability to modulate cell ROS
is well documented [81, 82]. Differently, it may be hypothe-
sised that the higher ROS level resulting upon NP treatment
could be ascribed to the increased O2
−• bioavailability bound
to the eNOS uncoupling. In a similar way, the higher level of
NOx found in HepG2 cells treated with OP and NP is likely
due to the “inverse regulative crosstalk” between the eNOS
and iNOS, whose expression is specifically modulated, the
former by OP and the latter by NP.
We have also to consider that one of the major detrimen-
tal effects driven by NP is the increase of protein nitrosation,
as testified by the accumulation of 3-NT in HepG2 cells. This
modification represents an important downstream marker of
nitro-oxidative stress, commonly attributed to a burst of per-
oxynitrite production. In the framework of NP treatment, the
increase of peroxynitrite formation results from the parallel
iNOS activation and eNOS uncoupling, increasing the NO
and the superoxide concentration, respectively.
The consequence of an increased bioavailability of ROS,
NO, and peroxynitrite has been investigated at mitochon-
drial level; here, the determination of mitochondrial mem-
brane potential (ΔμH+) revealed a slight though significant
decrease due to both OP and NP treatments. The evaluation
of the ETC efficiency proved that NP treatment impairs cyto-
chrome c oxidase (CcOx) activity by approximately 20%. In
this respect, it is worth considering that the respiratory chain
complexes and particularly CcOX react with both NO and
peroxynitrite [49, 50, 54, 83]. The reaction with peroxynitrite
can only be detrimental and irreversible [83]; the reaction of
complex IV with NO, instead, can occur within a physiolog-
ical edge, depending on the NO concentration and also on
the mitochondrial cell redox state [57]. For the sake of pro-
viding a feasible interpretation of the results herein reported,
the NP induced increase of NO bioavailability is not surpris-
ing, since the iNOS Vmax value (in the μM range) for NO
production is compatible with a significant inhibition of
complex IV [84]. OP, by activating the eNOS, producing
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Figure 4: Oxidative and nitrosative stress induced by OP and NP. Treated and untreated HepG2 cells were assayed for (a) the intracellular
ROS production of 106 cells/mL by 2,7-dichlorodihydrofluorescein diacetate (DCFDA). Data are expressed as percentage of the control
values, after normalization for total protein content. Data are the means± SEM; n = 3. p values were considered statistically significant by
ANOVA. (b) Evaluation of nitrite-nitrate (NOx) accumulation in the cell medium after incubation with 2,3-diaminonaphthalene (DAN)
(data± SEM; n = 3). p values were considered statistically significant by ANOVA. (c) 3-Nitrotyrosine (3-NT) quantification by
nitrotyrosine competitive ELISA assay on cell lysates. Data values are the means± SEM; n = 6. p values were considered statistically
significant by ANOVA.
8 Oxidative Medicine and Cellular Longevity
NO in the nM range, is expected to be responsible for tran-
sient effects, controlled by the complex regulatory modula-
tion of eNOS activity [85].
5. Conclusions
Thechanges inducedbyOPandNP in thebiochemical param-
eters related to NOmetabolism are summarized in Table 1.
Altogether, these findings confirm the endocrine-
disruptive action of the alkylphenols, OP and NP. Despite
their molecular similarity, these compounds are likely to
induce different signaling in HepG2 cells. It is feasible to
propose that through a direct interaction with ERs, while
OP realises an estrogen-mimicking activation of the eNOS
pathway, NP is rather deviating the signal towards a cascade
of events resulting in iNOS activation and eNOS uncou-
pling. Under these latter conditions, the production of
peroxynitrite (ONOO−) is maximised, leading to higher
levels of nitrotyrosine protein modification. The whole pic-
ture evokes a cell oxidative stress and damage, whose persis-
tency feasibly implies chronic tissue inflammation. This
notwithstanding, the suggestion of a milder cell toxicity for
OP with respect to NP is misleading. It should be considered
that by escaping the endogenous endocrine control, the
long-lasting bioavailability of OP results in a persistent pseu-
dohormonal overstimulation of the physiological endocrine
signal with elevated pathological potential.
In conclusion, upon mimicking or altering the endoge-
nous estrogenic cascade, these environmental contaminants
are able to interfere with the NO signaling pathway at differ-
ent molecular levels, in that producing different pathophysi-
ological effects, leading to alteration of NO bioavailability
and cell redox homeostasis, eventually with consequence on
mitochondrial bioenergetics.
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Figure 5: (a) Oxygen consumption rate. The respiratory rate of 3× 106 HepG2 cells was monitored after 24 h incubation with OP and NP.
Digitonin (dig) was added to permeabilise cells and allow the delivery of the compounds added along the trace. The specific ETC complex
activity has been evaluated upon the consecutive substrate/inhibitor addition as follows: pyruvate and malate (pyr/mal); ADP; rotenone
(rot); succinate (suc); antimycin A (ant a); and ascorbate plus N,N,N′,N′-tetramethyl-p-phenylenediamine (Asc/TMPD). The respiratory
control ratio (RCR) was determined as the O2 consumption rate measured at the ADP addition step over the rate measured at pyr/mal
step. Data values are the means± SEM; n = 4. p values were considered statistically significant by ANOVA. (b) Mitochondrial membrane
potential. The fluorescence intensity of the mitochondrial-imported probe JC-1 has been measured by cytofluorimetric analysis and
reported as the ratio between the red (aggregates) and green (monomer) fluorescent signal (data± SEM, n = 3). p values were considered
statistically significant by ANOVA.
Table 1: Nitric oxide-related parameters affected by octylphenol (OP) and nonylphenol (NP). P-eNOS: phosphorylated eNOS at the target
sites Ser 1177 and Thr 495. The eNOS uncoupling is featured by a decrease of P-Ser 1177 and increase of P-Thr 495 with respect to controls
that are typically 100% and 60% phosphorylated at these sites. Results are presented as the fold-change compared to controls or, in the case of
P-eNOS, as the percentage of phosphorylation with respect to total eNOS.
Effector eNOS P-eNOS iNOS NOx 3-NT ROS
OP
mRNA 1.57± 0.15 P-Ser 1177, ~100% mRNA 1.45± 0.14
2.54± 0.16 1.20± 0.08 1.41± 0.08
Protein 1.50± 0.09 P-Thr 495, ~60% Protein 1.08± 0.06
NP
mRNA 1.16± 0.07 P-Ser 1177, ~70% mRNA 2.01± 0.28
2.90± 0.19 1.55± 0.12 1.49± 0.07
Protein 0.94± 0.08 P-Thr 495, ~80% Protein 1.54± 0.09
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The results reported add information on the mechanisms
of action of NP and OP. Although additional studies also
including animal models are still missing, we feel that the
experimental work herein presented will contribute to the
understanding of the environmental pollution risk associated
to this class of compounds.
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